Skip to main content

NATURES SUNSHINE PRODUCTS INC

For the period ended Mar 20, 2025. Filed Mar 20, 2025.

View on SEC.gov

About this filing

What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.

Mar 20, 2025 · Filed Mar 20, 2025

NATR$10.87+5.9%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits

PProxy Summary

SUMMARY

2025 Annual Meeting of Shareholders

Time and DatePlaceRecord DateVoting
12:00 p.m. Mountain Daylight Time2901 West Bluegrass Blvd., Suite 100, Lehi, Utah 84043February 21, 2025Shareholders of record as of the Record Date are entitled to vote
April 30, 2025

Agenda and Voting Recommendations

ProposalDescriptionBoard RecommendationPage
1Election of Directorsü For each nominee10
2Advisory Resolution to Approve Compensation of Named Executive Officersü For24
3Ratification of Appointment of Independent Registered Public Accounting Firmü For47

The proxy solicitation materials are being sent on or about March 20, 2025 to our shareholders entitled to vote at the Annual Meeting.Pursuant to rules of the United States Securities and Exchange Commission (the “SEC”), we are providing our shareholders with access to our Notice of Annual Meeting of Shareholders, Proxy Statement and proxy card (referred to collectively as the “Proxy Materials”) and Annual Report on Form 10-K for the year ended December 31, 2024 (referred to as the “Annual Report”), online. You received by mail a Notice Regarding the Availability of Proxy Materials, including a notice of Annual Meeting of Shareholders (referred to as the “Notice”). Accordingly, you will not receive a printed copy of the Proxy Materials unless you have previously made an election to receive these materials in printed form. Instead, all shareholders will have the ability to access the Proxy Materials and Annual Report by visiting the website at http://www.proxyvote.com. Instructions on how to access the Proxy Materials online or to request a printed copy may be found in the Notice. In addition, all shareholders may request to receive proxy materials in printed form by mail on an ongoing basis.

22025 Proxy Statement

2024 PERFORMANCE

Our overall 2024 performance is highlighted in the metrics and charts below.
$454.4 Million$7.9 Million$40.3* Million$78.82**
NET SALESNET INCOMEADJUSTED EBITDATSR
*We define adjusted EBITDA, which is a non-GAAP financial measure, as net income/loss from continuing operations before taxes, depreciation, amortization and other income/loss adjusted to exclude share-based compensation expense and certain unusual (noted) adjustments for non- budgeted costs deemed appropriate by the Board. A reconciliation of net income to adjusted EBITDA is provided at the end of this Proxy Statement.**TSR is based on a comparison that assumes $100 in our common stock was invested on December 31, 2021.

*All amounts in ($) millions.

Nature's Sunshine Products, Inc.3

OUR CURRENT BOARD OF DIRECTORS

9 of 10Directors are Independent>4 yrs.Average Tenure
NAMEEXPERIENCEINDEPENDENTAGEDIRECTOR SINCECOMMITTEES
Richard MossChairman of the BoardFormer Chief Financial Officer of Hanesbrands Inc.ü672018AuditCompensation
Terrence MooreheadPresident & Chief Executive Officer of Nature's Sunshine Products, Inc.622018
Steven FaschingChief Financial Officer at Deckers Brandsü562024AuditCompensation
Curtis KopfGroup Vice President, Customer Experience at Insuletü592022GovernanceRisk Management (Chair)
Katie MayFormer Chief Executive Officer of ShippingEasyü582025CompensationGovernance
Tess RoeringFormer Chief Commercial Officer and Chief Marketing Officer at CorePower Yogaü562022AuditCompensation
Robert StrausPortfolio Manager at Wynnefield Capital Management, LLCü542017Compensation (Chair)Governance
Christopher TeetsFounding Partner of Red Mountain Capital Advisors LLCü522015Audit (Chair)Governance
Heidi WissmillerFormer Chief Growth Officer at Rodan + Fieldsü602020Governance (Chair)Risk Management
Rong YangChief Executive Officer of Fosun Pharma USA Inc.ü462022AuditRisk Management
42025 Proxy Statement
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.